«

»

Feb 06

The addition of evolocumab (Amgen, Thousand Oaks, CA) to a statin

The addition of evolocumab (Amgen, Thousand Oaks, CA) to a statin, compared with a statin alone, significantly lowered LDL–cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia, according to the top-line results of the LAPLACE-2 study announced this week. The full results of LAPLACE–2 will be presented by Dr Jennifer Robinson (University of Iowa, Iowa City) on March 30, 2014 during the late-breaking clinical–trials session of the American College of Cardiology Scientific Sessions in Washington, DC. Evolocumab is an investigational human monoclonal antibody for proprotein convertase subtilisin–kexin type 9 (PCSK9).

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>